Biosimilars driving Korean biopharma growth, report says

31 July 2019

Provisional data from the CPhI annual report shows that the overall competitiveness of the South Korean biopharmaceutical sector has grown by 9% in the last year.

Already home to more than 40 pharmaceutical companies, the Asian country is becoming a major center for the development of biosimilars, led by the success of Celltrion (Kosdaq: 068270) and Samsung Bioepis, a joint venture involving the US biotech company Biogen (Nasdaq: BIIB) and Samsung BioLogics.

The growth of Korea’s biopharmaceutical industry has also been driven by the surge of international partnerships, expansion in the export of finished formulations and a robust generics market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK